Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744740 | 0.86 | MAOA (0.46) | L3MBTL1CA1CA2CA9CA12 | |
| SCHEMBL26141744 | 0.84 | L3MBTL1 (0.45) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL19558646 | 0.84 | KDM4A (0.43) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL21455931 | 0.84 | L3MBTL1 (0.45) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL10547182 | 0.84 | ATR (0.46) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL29634114 | 0.84 | ATR (0.46) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL17309330 | 0.84 | KDM4A (0.43) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL508770 | 0.83 | ACACB (0.46) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL30097021 | 0.83 | ACACB (0.46) | KDM4AL3MBTL1CA1CA2CA9 | |
| SCHEMBL29085960 | 0.83 | L3MBTL1 (0.44) | KDM4AL3MBTL1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220219-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-09 | — | — | US | disclosed |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-22 | — | — | US | disclosed |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| WO-2020216669-A1 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-3700903-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | KDM4A 3183/4885L3MBTL1 3533/4885CA1 4703/4885 |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | KDM4A 1515/4885L3MBTL1 744/4885CA1 4715/4885 |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | KDM4A 1515/4885L3MBTL1 744/4885CA1 4715/4885 |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | BRCA1, VHL, TFEB | KDM4A 2278/4885L3MBTL1 2948/4885CA1 4603/4885 |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | KDM4A 3183/4885L3MBTL1 3533/4885CA1 4703/4885 |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | KDM4A 3183/4885L3MBTL1 3533/4885CA1 4703/4885 |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | GOT2, ABAT, OAT | KDM4A 3719/4885L3MBTL1 4278/4885CA1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.